Clinical Trial Update: Cetuximab in Third Line for Mutant APC, TP53 and RAS Patients With Refractory Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study of cetuximab as third-line therapy for refractory metastatic colorectal cancer with APC, TP53, and RAS mutations was terminated; results have be…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• ERBITUX (cetuximab)

Snippet

Sponsor: University of Utah | Conditions: Colorectal Cancer | Phase 2 | Status: TERMINATED | Results posted: 2025-05-06